Enliven Therapeutics Inc. (ELVN) Insider Trading
Total insider buys:
- $0.00
Total insider sells:
- $59,114,403.44
Most recent insider trade:
- July 10, 2025
Most active insider trader:
- Benjamin Hohl
| Trader Name | Date | Title | Amount | Price | Type | Total Value |
|---|---|---|---|---|---|---|
| Jan. 31, 2024 | Major Shareholder | 500,000 | $15.00 | Sell | $7,500,000.00 | |
| Jan. 30, 2024 | Director | 1,270 | $16.41 | Sell | $20,840.70 | |
| Jan. 29, 2024 | insider | 12,000 | $15.85 | Sell | $190,200.00 | |
| Jan. 29, 2024 | CFO | 3,250 | $15.81 | Sell | $51,382.50 | |
| Jan. 25, 2024 | CEO | 12,000 | $15.69 | Sell | $188,280.00 | |
| Jan. 22, 2024 | COO | 4,875 | $15.13 | Sell | $73,758.75 | |
| Jan. 2, 2024 | COO | 11,000 | $15.00 | Sell | $165,000.00 | |
| Jan. 2, 2024 | CFO | 9,383 | $15.01 | Sell | $140,838.83 | |
| Dec. 26, 2023 | CEO | 12,000 | $14.64 | Sell | $175,680.00 | |
| Dec. 26, 2023 | CFO | 100 | $15.00 | Sell | $1,500.00 | |
| Dec. 26, 2023 | COO | 102 | $15.01 | Sell | $1,531.02 | |
| Dec. 22, 2023 | COO | 983 | $15.03 | Sell | $14,774.49 | |
| Dec. 22, 2023 | CEO | 8,175 | $13.05 | Sell | $106,683.75 | |
| Dec. 22, 2023 | CFO | 1,030 | $15.07 | Sell | $15,522.10 | |
| Dec. 21, 2023 | insider | 20 | $13.00 | Sell | $260.00 | |
| Dec. 21, 2023 | Director | 7 | $13.00 | Sell | $91.00 | |
| Dec. 20, 2023 | CEO | 7,779 | $13.01 | Sell | $101,204.79 | |
| Dec. 19, 2023 | insider | 200 | $13.00 | Sell | $2,600.00 | |
| Dec. 19, 2023 | Director | 255 | $13.00 | Sell | $3,315.00 | |
| Nov. 3, 2023 | CEO | 8,026 | $13.08 | Sell | $104,980.08 | |
| Nov. 3, 2023 | insider | 8,546 | $13.08 | Sell | $111,781.68 | |
| Sept. 29, 2023 | insider | 12,000 | $13.62 | Sell | $163,440.00 | |
| Sept. 26, 2023 | Major Shareholder | 197,500 | $15.00 | Sell | $2,962,500.00 | |
| Sept. 25, 2023 | CEO | 12,000 | $13.81 | Sell | $165,720.00 | |
| Aug. 24, 2023 | Major Shareholder | 440,000 | $16.00 | Sell | $7,040,000.00 |
Insiders are selling Enliven Therapeutics Inc. stock.
The insider traders at Enliven Therapeutics Inc. are: Benjamin Hohl, Samuel Kintz, Anish Patel, Joseph P Lyssikatos, Richard A Heyman, Joseph P. Lyssikatos, Rahul D Ballal, 5Am Partners Vi, Llc, and Rishi Gupta
The most active insider trader at Enliven Therapeutics Inc. is Benjamin Hohl with 34 trades.
Rishi Gupta has sold the most Enliven Therapeutics Inc. stock with a total value of $45,754,524.00.
The most recent insider trade for Enliven Therapeutics Inc. was on July 10, 2025.
The single biggest insider sell for Enliven Therapeutics Inc. was from Rishi Gupta with a total value of $22,877,262.00 on May 16, 2024.